| 摘要: |
| ［摘要］ 目的 探讨美沙拉嗪联合三联活菌微生态制剂治疗轻中度溃疡性结肠炎的临床效果。方法 选取2013-06～2016-02该院消化内科治疗的轻中度溃疡性结肠炎患者90例，随机分为研究组和对照组，各45例。研究组采用美沙拉嗪联合三联活菌微生态制剂治疗，对照组仅采用美沙拉嗪治疗。均治疗8周，观察两组的疗效、不良反应等情况。结果 研究组显效24例，有效18例，无效3例。对照组显效13例，有效19例，无效13例，研究组疗效优于对照组（P<0.01）。治疗前研究组与对照组疾病活动指数（DAI）评分、肠镜积分、临床症状评分比较差异均无统计学意义（P>0.05）。治疗后研究组与对照组患者DAI评分、肠镜积分及临床症状评分均较治疗前降低，但研究组降低更明显，治疗后组间比较差异有统计学意义（P<0.01）。研究组的不良反应率（4.44%）低于对照组（6.67%），但差异无统计学意义（P>0.05）。结论 对轻中度溃疡性结肠炎患者采用美沙拉嗪联合三联活菌微生态制剂进行治疗，可以增强治疗效果，同时不会增加药物的不良反应发生率，值得推广应用。 |
| 关键词: 轻中度溃疡性结肠炎 美沙拉嗪 三联活菌微生态制剂 |
| DOI：10.3969/j.issn.1674-3806.2017.06.15 |
| 分类号:R 574.62 |
| 基金项目: |
|
| Effects of mesalazine combined with triple viable probiotics on the treatment of mild to moderate ulcerative colitis |
|
YANG Wei-feng, BAN Jie-hong, RAO Guan-hua, et al
|
|
Department of Gastroenterology, the First People′s Hospital of Qinzhou City, Guangxi 535000, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the clinical effects of mesalazine combined with triple viable probiotics on the treatment of mild to moderate ulcerative colitis.Methods 90 patients with mild to moderate ulcerative colitis who were hospitalized in the First People′s Hospital of Qinzhou City from June 2013 to February 2016 were randomly divided into the study group and the control group, with 45 cases in each group. The study group was treated with mesalazine combined with probiotics, while the control group was treated with mesalazine. All the patients were treated for 8 weeks and the therapeutic effect and the adverse reactions were compared between the two groups.Results The patients in the study group were markedly effective in 24 cases, effective in 18 cases and ineffective in 3 cases. The control group was markedly effective in 13 cases, effective in 19 cases and ineffective in 13 cases. The clinical effect of the study group was better than that of the control group(P<0.01). There were no significant differences in disease activity index score, colonoscopy integral and clinical symptom scores between the two groups before the treatment(P>0.05）. The scores of disease activity index, colonoscopy integral and clinical symptom were reduced in both of the two groups after the treatment, but those in the study group decreased more obviously than those in the control group after the treatment(P<0.01）. The adverse reaction rate of the study group(4.44 %）was lower than that of the control group(6.67%）, with no significant difference between the two groups(P>0.05).Conclusion Mesalazine combined with triple viable probiotics can enhance the therapeutic effect for the patients with mild to moderate ulcerative colitis, but can not increase the incidence of adverse drug reactions. |
| Key words: Mild to moderate ulcerative colitis Mesalazine Triple viable probiotics |
